MULTIPLE_MYELOMA

作品数：366被引量：615H指数：11
导出分析报告
相关作者：张林黄淑婷丁洁卫吕亚莉蔡真更多>>
相关机构：徐州医科大学第二军医大学浙江大学医学院附属第一医院绍兴文理学院更多>>
相关期刊：更多>>
相关基金：国家自然科学基金国家重点基础研究发展计划北京市自然科学基金湖北省自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
A review on pathobiology of circulating tumour plasma cells:The sine qua non of poor prognosis in plasma cell neoplasms
《Oncology Research》2025年第5期1055-1068,共14页PRATIBHA SUKU AISHWARYA DASH ARAVIND RADHAKRISHNAN PANKAJ MALHOTRA MAN UPDESH SINGH SACHDEVA 
Circulating plasma cells(CPCs)in patients of plasma cell neoplasm have been an area of intense research in recent decades.Circulating tumor plasma cells(CTPCs)might represent a sub-clone of tumor cells that have exite...
关键词：Circulating Plasma Cells(CPCs) Multiple Myeloma(MM) Flow cytometry Circulating Tumor Plasma Cells(CTPCs) Microenvironment Monoclonal gammopathy 
Characteristics and outcomes of secondary acute lymphoblastic leukemia(sALL)after multiple myeloma(MM):SEER data analysis in a single-center institution
《Cancer Pathogenesis and Therapy》2025年第1期76-80,共5页Jing Jia Jiahui Yin Chuanying Geng Aijun Liu 
Background:Secondary acute lymphoblastic leukemia(sALL)is rare in patients diagnosed with antecedent multiple myeloma(MM).This study aimed to elucidate the clinical features and outcomes of patients with sALL after MM...
关键词：Multiple myeloma NEOPLASMS Second primary Precursorcell lymphoblastic leukemialymphoma SEERprogram Survival 
NUF2 overexpression predicts poor outcomes in multiple myeloma
《Genes & Diseases》2025年第1期141-143,共3页Shanshan Zhang Li Zhang Linjing Cai Huan Chen Yuqi Wang Youhai Yuan Hanzhen Zhang Xiaolei Wei 
supported by Natural Science Foundation:of Guangdong,China(No.2024A04J5216);the Technology Project of Guangzhou City(Guangdong,China)(No.202102020937);the Outstanding Youth Development Scheme of Nanfang Hospital,Southern Medical University(Guangdong,China)(No.2019J011).
Multiple myeloma(MM)is the second most common hematologic malignancy and is characterized by the expansion of clonally plasma cells and related organ or tissue damage.1 The clinical behavior,response,and survival of M...
关键词：MYELOMA CLINICAL DAMAGE 
Using protein turnover assay to explore the drug mechanism of Carfilzomib
《Acta Biochimica et Biophysica Sinica》2025年第2期209-222,共14页Yonghui Tao Xinyu Ding Caiwei Jia Chengcheng Wang Chuanyin Li 
supported by the grants from the Shanghai Sailing Program(19YF1444700);the National Natural Science Foundation of China(Nos.31900804 and 82304563);the Guizhou Province Science and Technology Foundation([2020]1Y086);the Science and Technology Foundation of Guizhou Provincial Health Commission(No.gzwkj2022-219).
Carfilzomib(CFZ)is the second-generation proteasome inhibitor that is approved by Food and Drug Administration(FDA)of USA for the treatment of relapsed and refractory multiple myeloma.Although the preclinical and clin...
关键词：Carfilzomib multiple myeloma PROFILING protein homeostasis 
IGF2BP1 promotes multiple myeloma with chromosome 1q gain via increasing CDC5L expression in an m6A-dependent manner
《Genes & Diseases》2025年第1期298-311,共14页Jiadai Xu Yawen Wang Liang Ren Panpan Li Peng Liu 
supported by the National Natural Science Foundation of China(No.82100215);Natural Science Foundation of Shanghai,China(No.22ZR1411400);Natural Science Foundation of Fujian Province,China(No.2023J05291).
Multiple myeloma(MM)patients with chromosome 1q gain(1q+)are clinically and biologically heterogeneous.The underlying molecular mechanisms are still under investigation,while the identification of targets for effectiv...
关键词：CDC5L Chromosome 1q gain IGF2BP1 Multiple myeloma N6-methyladenosine 
Extramedullary plasmacytoma with the uvula as first affected site:A case report
《World Journal of Clinical Oncology》2025年第1期53-58,共6页Jing Yang Hui Peng Sheng-Ke Tu Min Li Kui Song 
Supported by Hunan Innovative Province Construction Special Task Book,No.2021SK4050;Innovation Platform and Talent Program of Hunan Province,No.2023JJ30609.
BACKGROUND Extramedullary plasmacytoma(EMP)represents one of the rarer forms of plasma cell malignancies,capable of impacting a variety of tissues and organs throughout the body.The majority of EMP cases are predomina...
关键词：Extramedullary plasmacytoma PLASMACYTOMA UVULA Multiple myeloma Case report 
Advancements in drugs restructured with nanomedicines for multiple myeloma treatment被引量：1
《Science China Materials》2024年第12期3780-3795,共16页Zhaoyun Liu Hongli Shen Hui Liu Kai Ding Jia Song Jingtian Zhang Dan Ding Rong Fu 
supported by the National Natural Science Foundation of China Youth Project(81900131);Tianjin Municipal Natural Science Foundation(18JCQNJC80400);Tianjin Education Commission Research Project(2018KJ043);Tianjin Education Commission Research Project(2018KJ045);Tianjin Science and Technology Planning Project(20YFZCSY00060);Tianjin Municipal Health Commission Youth Project(TJWJ2021QN001);the Medjaden Academy&Research Foundation for Young Scientists(MJR20221011);Tianjin Key Medical Discipline(Specialty)Construction project(XZDXK-028A);Tianjin Municipal Health Health Science and Technology Project(TJWJ2023XK003).
Multiple myeloma(MM)is an incurable malignancy of clonal plasma cells,characterized by high relapse rates and rapid development of drug resistance.The emergence of proteasome inhibitors has dramatically improved the t...
关键词：plasma cell disease NANOTECHNOLOGY HEMATOLOGY proteasome inhibitors 
Biomimetic cell membrane decorated ZIF-8 nanocarriers with IR-780 and doxorubicin loading for multiple myeloma treatment
《Aggregate》2024年第6期332-339,共8页Guangtao Gao Junyi Che Peipei Xu Bing Chen Yuanjin Zhao 
National Key Research and Development Program of China,Grant/Award Number:2022YFA1105304;National Natural Science Foundation of China,Grant/Award Numbers:32201088,82273954;Natural Science Foundation of Jiangsu Province,Grant/Award Number:BK20210010;Fundings for Clinical Trials from the Affiliated Drum Tower Hospital,Medical School of Nanjing University,Grant/Award Number:2022-LCYJ-MS-16。
Several therapeutic drugs including heptamethine cyanine dye(IR-780),doxorubicin(DOX),and others have exhibited positive outcomes in the treatment of multiple myeloma(MM).However,curing MM is still hampered by undesir...
关键词：BIOMIMETIC bone marrow homing cell membrane drug delivery multiple myeloma PDT/PTT 
Expression and clinica1l significanceof CCL17,CCL22,and CCR4 in newly diagnosed multiple myeloma
《China Medical Abstracts(Internal Medicine)》2024年第4期226-227,共2页XIAO Zifan 
Objective To study the expressions of C-C class chemokine 17(CCL17),C-C class chemokine 22(CCL22),and C-C chemokine receptor 4(CCR4)in newly diagnosed multiple myeloma(NDMM)for analyzing their correlations with clinic...
关键词：CCR4 CCL22 CCL17 
Dynamic frailty-tailored therapy(DynaFiT):A proof-of-concept study in elderly patients with newly diagnosed multiple myeloma
《Blood Science》2024年第4期70-72,共3页Yun Dai Fengyan Jin 
funded by the National Natural Science Foundation of China(No.81471165,81670190,81670189,81870160,81971108,82270207,and 82370202);the Science and Technology Development Program of the Jilin Province(No.20190201042JC,20190201163JC,YDZJ202301ZYTS021,and 20210509010RQ);Interdisciplinary Integration and Innovation Project of Jilin University.
Emerging evidence indicates that the fitness/frailty status of elderly patients with multiple myeloma(MM)is highly dynamic,influenced by factors such as aging,disease progression,and treatment.This underscores the imp...
关键词：PATIENTS TREATMENT MYELOMA 
全选清除导出
共37页<12345678910>
检索报告 对象比较 聚类工具 使用帮助 返回顶部